Skip to main content

Dexrazoxane Dosage

Medically reviewed by Last updated on Jan 22, 2021.

Applies to the following strengths: 250 mg; 500 mg

Usual Adult Dose for Cardiomyopathy Prophylaxis

Zinecard (R):

Dosage ratio of dexrazoxane to doxorubicin is 10:1 (e.g. 500 mg/m2 dexrazoxane to 50 mg/m2 doxorubicin)
-Administer via IV infusion over 15 minutes.
-DO NOT administer via IV push.
-Administer doxorubicin within 30 minutes of completion of dexrazoxane infusion; do not administer doxorubicin before dexrazoxane.

-Do not use with the initiation of doxorubicin therapy.

Use(s): Reducing incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin.

Usual Adult Dose for Extravasation

Totect (R):

Recommended doses:
Day one: 1000 mg/m2 IV over 1 to 2 hours
Day two: 1000 mg/m2 IV over 1 to 2 hours
Day three: 500 mg/m2 IV over 1 to 2 hours

Maximum doses:
Day one: 2000 mg
Day two: 2000 mg
Day three: 1000 mg

-Product must be diluted with 50 mL of 0.167 M sodium lactate injection solution prior to administration.
-Initiate first infusion as soon as possible and within the first 6 hours of extravasation.
-Start day 2 and 3 treatments at the same hour as the first day (give or take 3 hours).
-Remove cooling features such as ice packs (if used) at least 15 minutes before administration to allow sufficient blood flow to extravasation area.

Use(s): Extravasation resulting from intravenous anthracycline chemotherapy

Renal Dose Adjustments

CrCl under 40 mL/min: Reduce dose by half

Liver Dose Adjustments

Extravasation: Not recommended in hepatic impairment.
-Perform routing liver function tests before each administration if patient has known liver function disorders.

Cardiomyopathy prophylaxis: Since doxorubicin dose reduction is recommended, reduce dose of dexrazoxane proportionally (maintaining the 10:1 ratio).


-Do not use with non-anthracycline chemotherapy regimens.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.